IMBRUVICA Ibrutinib 140mg

ADDITIONAL INFORMATION

Strengths available :  140mg

Storage : Store at temperature below 30°C

Dosage :

• Administer IMBRUVICA orally once daily at approximately the same time each day.
• Swallow the capsules whole with water.
• Do not open, break, or chew the capsules.

Mantle Cell Lymphoma and Marginal Zone Lymphoma

​The recommended dose of IMBRUVICA for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia

The recommended dose of IMBRUVICA for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

​Chronic Graft versus Host Disease

​The recommended dose of IMBRUVICA for cGVHD is 420 mg (three 140 mg capsules) orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRU